Enveric Biosciences, Inc.
ENVB· Nasdaq
ENVBEnveric Biosciences, Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001493152-26-038418
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$3.03M | -$2.52M | -$1.88M | -$6.36M |
| EPS Diluted | -$0.76 | -$11.65 | -$3.72 | -$3.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
